Qualigen Therapeutics, Inc.
QLGN
$3.11
$0.103.32%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 54.71% | 28.99% | 19.09% | 9.44% | -36.94% |
| Total Depreciation and Amortization | 50.00% | 50.00% | -95.25% | -97.49% | -98.87% |
| Total Amortization of Deferred Charges | -40.95% | 27.61% | 95.01% | -- | -- |
| Total Other Non-Cash Items | -140.87% | -73.29% | -82.74% | -90.00% | 174.21% |
| Change in Net Operating Assets | -64.69% | -54.98% | 1,528.10% | 258.30% | 230.75% |
| Cash from Operations | -41.62% | 36.26% | 29.55% | 22.22% | 50.65% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -117.79% | 1,080.52% | 1,097.74% | 1,825.04% | -- |
| Cash from Investing | -117.79% | 1,058.45% | 1,428.72% | 2,393.80% | 8,469.27% |
| Total Debt Issued | 19.67% | -49.20% | -83.64% | -- | -- |
| Total Debt Repaid | -379.55% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 99.93% |
| Cash from Financing | 96.25% | -63.02% | -102.58% | -118.90% | -69.80% |
| Foreign Exchange rate Adjustments | -- | -204.42% | -232.26% | 100.00% | 85.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -722.70% | 85.38% | 53.74% | 36.77% | 88.14% |
